Chinese biotech's $53m IPO joins flurry of HK market activity
Even if Hong Kong's social landscape remains fractured, biotech firms continue to be lured to the HKEX, with Ascentage Pharma the latest to float.
October 23, 2019
While other financial markets struggle, commodities maintain a strategic attraction to banks. A structural shift towards long-term higher demand from China and other industrialising economies makes a persuasive argument for adding staff when other divisions are contracting — human resources departments need to show a great deal of contrarian and intellectual rigour to resist.
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].